

---

Basic Research and Clinical Aspects of *Pseudomonas aeruginosa*

---

# Antibiotics and Chemotherapy

Vol. 39

Series Editor  
*H. Schönfeld*, Grenzach



---

Basel · München · Paris · London · New York · New Delhi · Singapore · Tokyo · Sydney

International Symposium on *Pseudomonas aeruginosa*, Tübingen, June 20–22, 1986

---

# Basic Research and Clinical Aspects of *Pseudomonas aeruginosa*

Volume Editors

*G. Döring*, Tübingen

*I.A. Holder*, Cincinnati, Ohio

*K. Botzenhart*, Tübingen

56 figures and 66 tables, 1987



---

Basel · München · Paris · London · New York · New Delhi · Singapore · Tokyo · Sydney

---

# Antibiotics and Chemotherapy

---

## Library of Congress Cataloging-in-Publication Data

International Symposium on Pseudomonas Aeruginosa  
(1986: Tübingen, Germany)

Basic research and clinical aspects of Pseudomonas aeruginosa.  
(Antibiotics and chemotherapy; vol. 39)

Includes bibliographies and index.

1. Pseudomonas aeruginosa-Congresses. 2. Pseudomonas diseases-Chemotherapy-Congresses. I. Döring, G. II. Holder, Ian Alan. III. Botzenhardt, K. IV. Title. V. Series. [DNLM: 1. Pseudomonas Aeruginosa-congresses. 2. Pseudomonas Infections-congresses. W1 AN855G v. 39 / WC 330 I61b 1986]

RM260.A55 vol. 39 615.5'8 87-15277 [RC116.P7] [617'.22]

ISBN 3-8055-4541-X

---

## Drug Dosage

The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

---

## All rights reserved.

No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

- © Copyright 1987 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)  
Printed in Switzerland by Thür AG Offsetdruck, Pratteln  
ISBN 3-8055-4541-X

---

## Contents

Foreword . . . . .	IX
<i>Epidemiology</i>	
Botzenhart, K. (Tübingen); Rüden, H. (Berlin): Hospital Infections Caused by <i>Pseudomonas aeruginosa</i> . . . . .	1
<i>Burn Infections</i>	
Ninnemann, J.L. (San Diego, Calif.): Clinical and Immune Status of Burn Patients	16
Neely, A.N.; Holder, I.A. (Cincinnati, Ohio): Use of Passive Immunotherapy in the Treatment of Experimental <i>Pseudomonas aeruginosa</i> Infections in Burns . . .	26
<i>Pulmonary Infections</i>	
Vaerman, J.P. (Brussels): The Secretory Immune System . . . . .	41
Pennington, J.E. (Boston, Mass.): Therapeutic Strategies for <i>Pseudomonas aeruginosa</i> Pneumonia in the Myelosuppressed Host . . . . .	51
Høiby, N. (Copenhagen); Döring, G. (Tübingen); Schiøtz, P.O. (Copenhagen): Pathogenic Mechanisms of Chronic <i>Pseudomonas aeruginosa</i> Infections in Cystic Fibrosis Patients . . . . .	60
<i>Eye Infections</i>	
Foster, C.S. (Boston, Mass.): Eye and Immunity . . . . .	77
Berk, R.S.; Hazlett, L.D. (Detroit, Mich.); Beisel, K.W. (Baltimore, Md.): Genetic Studies on Resistant and Susceptibility Genes Controlling the Mouse Cornea to Infection with <i>Pseudomonas aeruginosa</i> . . . . .	83
Thiel, H.-J.; Steuhl, K.-P.; Döring, G. (Tübingen): Therapy of <i>Pseudomonas aeruginosa</i> Eye Infections . . . . .	92

Kessler, E. (Tel Hashomer); Blumberg, S. (Tel Aviv): Specific Inhibitors of *Pseudomonas aeruginosa* Elastase as Potential Drugs for the Treatment of *Pseudomonas* Keratitis . . . . . 102

*Virulence Factors*

Sorensen, R.U. (Cleveland, Ohio); Klinger, J.D. (Boston, Mass.): Biological Effects of *Pseudomonas aeruginosa* Phenazine Pigments . . . . . 113

Cochrane, D.M.G.; Anwar, H.; Brown, M.R.W. (Birmingham); Lam, K.; Costerton, J.W. (Calgary, Alta.): Iron Deprivation in vivo: Surface Protein Antigens of *Pseudomonas aeruginosa* in Infection . . . . . 125

Döring, G.; Maier, M.; Müller, E.; Bibi, Z. (Tübingen); Tümmler, B. (Hannover); Kharazmi, A. (Copenhagen): Virulence Factors of *Pseudomonas aeruginosa* . 136

Saelinger, C.B.; Morris, R.E. (Cincinnati, Ohio): Intracellular Trafficking of *Pseudomonas* Exotoxin A . . . . . 149

Woods, D.F. (Calgary, Alta.): Pathogenesis of Acute and Chronic *Pseudomonas aeruginosa* Infections . . . . . 160

*Antibiotics*

Moore, R.A.; Woodruff, W.A.; Hancock, R.E.W. (Vancouver, B.C.): Antibiotic Uptake Pathways across the Outer Membrane of *Pseudomonas aeruginosa* . 172

Dalhoff, A. (Wuppertal): Pleiotropic Actions of Aminoglycosides . . . . . 182

Dalhoff, A. (Wuppertal); Döring, G. (Tübingen): Action of Quinolones on Gene Expression and Bacterial Membranes . . . . . 205

*Immunotherapy*

Homma, J.Y.; Tanimoto, H. (Tokyo): A Multicomponent *Pseudomonas aeruginosa* Vaccine Consisting of Toxoids of Protease, Elastase, Exotoxin A and a Common Protective Antigen (OEP). Application in Patients with Diffuse Panbronchiolitis . . . . . 215

Collins, M.S.; Tsay, G.C.; Hector, R.F.; Roby, R.E.; Dorsey, J.H. (Berkeley, Calif.): Therapy of Experimental *Pseudomonas* Burn Wound Sepsis with Ciprofloxacin and *Pseudomonas* Immune Globulin . . . . . 222

Montie, T.C. (Knoxville, Tenn.); Drake, D. (Louisville, Ky.); Sellin, H.; Slater, O.; Edmonds, S. (Knoxville, Tenn.): Motility, Virulence, and Protection with a Flagella Vaccine against *Pseudomonas aeruginosa* Infection . . . . . 232

Cryz, S.J., Jr.; Furer, E. (Berne); Sadoff, J.C. (Washington, D.C.); Germanier, R. (Berne): A Polyvalent *Pseudomonas aeruginosa* O-Polysaccharide-Toxin A Conjugate Vaccine . . . . . 249

*Genetics*

Haas, D.; Jann, A.; Reimann, C.; Lüthi, E.; Leisinger, T. (Zürich): Chromosome Organization in *Pseudomonas aeruginosa*. Clustering and Scattering of Genes Specifying Four Arginine Catabolic Pathways . . . . . 256

Vasil, M.L.; Ogle, J.W.; Grant, C.C.R.; Vasil, A.I. (Denver, Colo.): Recombinant DNA Approaches to the Study of the Regulation of Virulence Factors and Epidemiology of *Pseudomonas aeruginosa* . . . . . 264

Hindahl, M.S.; Frank, D.W.; Iglewski, B.H. (Portland, Oreg.): Molecular Studies of a Positive Regulator of Toxin A Synthesis in *Pseudomonas aeruginosa* . . . . . 279

Cornelis, P.; Moguilevsky, N.; Jacques, J.F.; Masson, P.L. (Brussels): Study of the Siderophores and Receptors in Different Clinical Isolates of *Pseudomonas aeruginosa* . . . . . 290

Subject Index . . . . . 307



---

## Foreword

*Pseudomonas aeruginosa* continues to be a mysterious microorganism, and many questions concerning its pathogenicity in human infections such as adherence, mucoid and nonmucoid growth, virulence in acute and chronic infections, genetic organization, and effective anti-*Pseudomonas* therapy are today only incompletely understood and remain to be answered. Thus, one can approach this opportunistic pathogen from many points of view, and the increasing number of publications by clinicians, immunologists, microbiologists, and geneticists show how attractive *P. aeruginosa* is.

The ultimate goal in research on infectious diseases is their prevention. The increasing specialization in science today may often obscure this goal. Transparent communication and fruitful cooperation between scientists are, therefore, needed. This was the purpose of the symposium 'Basic research and clinical aspects of *Pseudomonas aeruginosa*', held June 20–22, 1986, in Tübingen, FRG, where the most important infections caused by *P. aeruginosa* as well as topics on virulence, therapy, and genetics were extensively discussed. We would be happy if the reader of this book receives productive stimuli for his own work.

We thank the Deutsche Forschungsgemeinschaft and the companies Amour Pharmaceuticals, Api Bio-Mérieux, Bayer, Beecham Laboratories, Bode Chemie, Braun-Melsungen, Cascan, Cyanamid, Deutsche Pharmacia, Dr. G. Mann, Dr. K. Thomae, Dr. Winzer, Flow Laboratories, Eli Lilly, Marion Laboratories, E. Merck, Hoechst, Hoffmann-La Roche, Immuno, Miles, Möller Schwind Coopervision, Mundipharma, Pfizer, and Takeda for their generous financial support. The stimulating suggestions of our colleagues H.-J. Thiel and W. Werner have been very helpful for the realization of the symposium.

We also gratefully acknowledge the assistance of A. Albus, C. Berg, Z. Bibi, G. Botzenhart, E. Müller, and M. Przbilla before and during the symposium. Lastly, we wish to express gratitude to W. Schneider-Lastin and M. Beck, whose constant cooperation in the preparation of manuscripts for this book was invaluable, and to the excellent scientists who were united in Tübingen by their common interest in *P. aeruginosa*.

*Gerd Döring*  
*Ian A. Holder*  
*Konrad Botzenhart*